Sipuleucel-T (Provenge®) for castration-resistant prostate cancer

BJU International

Volumn 110, Issue , 2012, Pages

  Di Lorenzo, Giuseppe ^a   Ferro, Matteo ^a   Buonerba, Carlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

immunotherapy; prostate cancer; Provenge; sipuleucel T

Indexed keywords

DOCETAXEL; PLACEBO; SIPULEUCEL T;

APPLICATION SITE INFECTION; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILL; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; FEVER; HEADACHE; HUMAN; HYPERTENSION; MONOTHERAPY; MYALGIA; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; VOMITING;

AGED; CANCER VACCINES; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TISSUE EXTRACTS; TREATMENT OUTCOME; UNITED STATES;

EID: 84863548973     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10790.x     Document Type: Review

References (21)

1. Sonpavde G, Sternberg CN,. Contemporary management of metastatic castration-resistant prostate cancer. Curr Opin Urol 2011; 21: 241-7
2. Drake CG,. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10: 580-93
3. Higano CS, Small EJ, Schellhammer P, et al,. Sipuleucel-T. Nat Rev Drug Discov 2010; 9: 513-4
4. Tarassoff CP, Arlen PM, Gulley JL,. Therapeutic vaccines for prostate cancer. Oncologist 2006; 11: 451-62
5. Kantoff PW, Higano CS, Shore ND, et al,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
6. Higano CS, Schellhammer PF, Small EJ, et al,. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-9
7. Longo DL,. New therapies for castration-resistant prostate cancer. N Engl J Med 2010; 363: 479-81
8. Chambers JD, Neumann PJ,. Listening to Provenge-what a costly cancer treatment says about future medicare policy. N Engl J Med 2011; 364: 1687-9
9. Provenge-FDA full prescribing information. Available at:. Accessed 10 November 2011
10. Petrylak DP, Dawson NA, Gardner T, et al,. Persistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studies. J Clin Oncol 2010; 28 (Suppl.): 15s (abstr 4551)
11. Sims RB, Lin L, dela Rosa CP, et al,. Elevated eosinophils following treatment with sipuleucel-T in men with prostate cancer is associated with antigen-specific immune response and prolonged survival. 52nd American Society of Hematology Annual Meeting and Exposition, December 4-7, 2010, Orlando, FL
12. Sims RB, Wener MH, dela Rosa CP, et al,. Increased gamma globulin following immunotherapy with sipuleucel-T is associated with antigen-specific antibody responses. 52nd American Society of Hematology Annual Meeting and Exposition, December 4-7, 2010, Orlando, FL
13. Sheikh NA, Wesley JD, Chadwick E, et al,. Characterization of antigen-specific T-cell activation and cytokine expression induced by sipuleucel-T. J Clin Oncol 2011; 29 (Suppl. 7): (abstr 155)
14. Stewart FP, Dela Rosa CP, Sheik NA, et al,. Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer. J Clin Oncol 2010; 28: 4552
15. Beinart G, Rini BI, Weinberg V, Small EJ,. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005; 4: 55-60
16. Beer TM, Bernstein GT, Corman JM, et al,. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). J Clin Oncol 2007; 25: 5059
17. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ,. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006; 107: 67-74
18. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN,. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010; 70: 983-1000
19. Di Lorenzo G, Buonerba C, Kantoff PW,. Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011; 8: 551-61
20. Di Lorenzo G, Buonerba C,. Kidney cancer: overall survival is an unsuitable primary end point. Nat Rev Urol 2010; 7: 367-8
21. Medicare to cover Dendreon's prostate drug. 30 June 2011. Reuters. Available at:. Accessed November 2011